The National Institutes of Health is accepting grant applications to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience.
Donor Name: National Institutes of Health
State: All States
County: All Counties
Territory: Commonwealth of Puerto Rico, Guam, U.S. Virgin Islands, American Samoa, and Commonwealth of Northern Mariana Islands
Type of Grant: Grant
Deadline: 08/07/2023
Size of the Grant: $400,000
Grant Duration: 2 years
Details:
The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these ESIs to develop new research directions and to position these researchers to be competitive for new research funding (e.g., R01). Proposed projects must use NHPs as preclinical models for HIV/AIDS research.
The 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research identifies several high-priority areas for HIV/AIDS treatment and prevention for which NHP models are highly relevant.
- Reduce the Incidence of HIV, including supporting the development of safe and effective vaccines, microbicides and pre-exposure prophylaxis.
- Develop Next-Generation HIV Therapies with improved safety and ease of use.
- Conduct Research Toward HIV Cure.
- Address HIV-Associated Comorbidities, Coinfections, and Complications through research designed to decrease and/or manage these conditions.
- Advance Cross-Cutting Areas of research in the basic sciences, behavioral and social sciences, epidemiology, implementation science, information dissemination, and research training.
The topics of interest to this NOFO include, but are not limited to:
- Vaccines, vaccine adjuvants and other novel antiretroviral therapy-free approaches to viral remission or eradication directed towards Simian Immunodeficiency Virus/Simian-Human Immunodeficiency Virus (SIV/SHIV) at various stages of the lifespan, including neonates and infants;
- Non-vaccine prevention, such as oral pre-exposure prophylaxis neutralizing monoclonal antibodies, or mucosal microbicides;
- Antiretrovirals, safe and effective combination antiretroviral treatment (cART), or combined drug/immunotherapeutic approaches;
- Identification, characterization, and therapeutic targeting of anatomic sanctuary sites that serve as latent reservoirs of the virus during antiretroviral treatment (ART);
- Identification of biomarkers for predicting viral remission or reactivation/rebound of latent virus;
- Impact of co-morbidities and co-infections on SIV/SHIV acquisition/transmission, progression to AIDS, and/or interactions with treatment modality; and
- Imaging and monitoring/tracking SIV/SHIV, immune cells, and anti-SIV/SHIV antibodies.
Funding Information
No more than $200,000 in direct costs may be requested in any single year. The combined budget may not exceed $400,000 direct costs for the two-year period.
Award Project Period
The total project period may not exceed 2 years.
Eligibility Criteria
- Higher Education Institutions
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
- The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Local Governments
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Federal Government
- U.S. Territory or Possession
For more information, visit Grants.gov.
